A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

DelveInsight’s Refractory Metastatic Melanoma pipeline report depicts a robust space with 4+ active players working to ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, ...

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to ...

We report, for the first time to the best of our knowledge, the largest cohort of serial hs-TnI surveillance in patients diagnosed with cancer and treated with ICIs therapies,” the researchers wrote.

Total aggregate value of the drugs generating the highest sales in 2024 rose 6.5% vs. 2023, and jumped 53% over five years.

In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated ...